Clareo Health | Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug
Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants ≥ 40 years of age at baseline visit
Patients with confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD)
Patients who have been on Spiriva® HandiHaler® for ≥ 6 weeks at baseline visit
Patients for whom a switch from Spiriva® HandiHaler® to Spiriva® Respimat® was planned prior to study inclusion. If additional inhalative COPD drugs (AICDs) are used: AICD treatment must have been stable for at least 6 weeks before study inclusion
Signed written informed consent form to participation
You may not be if
Patients who have contraindications to Spiriva® Respimat® according to the current prescribing information label/ summary of product characteristics (SmPC)
Patients who have signs of a current, acute respiratory tract infection 2 weeks prior visit 1
Patients for whom further follow-up will not be possible at the enrolling site during the planned observational period (of approximately 8 weeks)
Patients with confirmed diagnosis of only asthma
Patients who had \> 1 moderate to severe exacerbation(s) within the last 6 weeks prior to study inclusion
Patients who are pregnant or breastfeeding
Patients participating in an ongoing interventional study
